Two and a half weeks af­ter Sesen Bio pushed back against an in­vestor group op­pos­ing a merg­er with Caris­ma Ther­a­peu­tics, the biotech is mov­ing for­ward and call­ing a share­hold­er meet­ing for a vote.

A state­ment put out Thurs­day af­ter­noon high­light­ed how the com­pa­ny is in the mid­dle of merg­ing ef­forts with the pri­vate CAR-M play­er, as Sesen an­nounced it filed ‘de­fin­i­tive proxy ma­te­ri­als’ with the SEC as part of the process.

Be­yond the proxy fil­ing, Sesen will start to mail out the state­ment and merg­er prospec­tus to share­hold­ers ear­ly next week and has sched­uled an all-vir­tu­al share­hold­er meet­ing for March 2 at 10 a.m. ET.

As of Jan­u­ary 17, all cur­rent share­hold­ers will be able to vote.

The vote it­self, de­tailed in a let­ter sent to share­hold­ers, is cen­tered around five pro­pos­als for which the board wants share­hold­ers to vote:

• Ap­proval to is­sue shares of Sesen Bio com­mon stock to Caris­ma stock­hold­ers, per the merg­er agree­ment
• Ap­proval to amend Sesen’s cer­tifi­cate of cor­po­ra­tion to ef­fect the re­verse stock split and re­duce Sesen Bio’s shares
• Ap­prove an amend­ment and re­state­ment of a 2014 In­cen­tive Plan
• Ap­prove an amend­ment to the 2014 em­ploy­ee stock pur­chase plan
• Ap­prove of an ad­journ­ment of the spe­cial meet­ing, if nec­es­sary, to so­lic­it ad­di­tion­al prox­ies

At the same time the vote was de­tailed, Sesen re­it­er­at­ed some of its pre­vi­ous claims against the op­pos­ing in­vestor group. Be­yond Sesen’s claims that the merg­er would have im­me­di­ate ben­e­fits, the biotech took the op­por­tu­ni­ty to say that the group’s pro­pos­al would leave val­ue on the ta­ble.

This fol­lows a back-and-forth ear­li­er this month when the group de­cried the deal as “il­log­i­cal” and “val­ue-de­struc­tive.” Sesen fired back that the group’s pro­pos­al to end the merg­er and re­turn all the com­pa­ny’s cash to share­hold­ers re­lies on a dis­tri­b­u­tion sce­nario that isn’t fea­si­ble.

If the vote pass­es, Sesen says the merg­er should be com­plete by the end of Q1, sub­ject to oth­er clos­ing con­di­tions. A rep­re­sen­ta­tive for the in­vestor group did not im­me­di­ate­ly re­spond to End­points News.

New York City is investing $20 million in biotech this year in the form of a 50,000-square-foot “innovation space” at the Brooklyn Navy Yard, complete with offices, research laboratories and events and programming space to grow biotech startups and companies.

Mayor Eric Adams said during his State of The City Address last Thursday that there will be an “emphasis” on making more opportunities for women and people of color to further diversify the industry. The City first reported the news.

Boehringer Ingelheim uncorked some positive results suggesting that Spevigo can help prevent flare-ups in patients with a severe form of psoriasis, months after the drug was approved to treat existing flares.

Spevigo, an IL-36R antibody also known as spesolimab, met its primary and a key secondary endpoint in the Phase IIb EFFISAYIL 2 trial in patients with generalized pustular psoriasis (GPP), Boehringer announced on Monday. While the company is keeping the hard numbers under wraps until later this year, it said in a news release that it anticipates sharing the results with regulators.

AstraZeneca, Novo Nordisk, and Sanofi won an appeals court win on Monday, as the US Court of Appeals for the Third Circuit found that the companies cannot be forced to provide 340B-discounted drugs purchased by hospitals from an unlimited number of community and specialty pharmacies.

“Legal duties do not spring from silence,” the decision says as the court makes clear that the federal government’s interpretation of the “supposed requirement” that the 340B program compels drugmakers to supply their discounted drugs to an unlimited number of contract pharmacies is not correct, noting:

A US appeals court has ruled against Johnson & Johnson’s use of bankruptcy to deal with mounting talc lawsuits, deciding that doing so would “create a legal blind spot.”

The Third Circuit Court of Appeals reversed a previous bankruptcy court decision on Monday, calling for the dismissal of a Chapter 11 filing by J&J’s subsidiary LTL Management.

Faced with more than 38,000 lawsuits alleging its talc-based products caused cancer, J&J spun its talc liabilities into a separate company called LTL Management back in October 2021 and filed for bankruptcy, a controversial move colloquially referred to as a “Texas two-step” bankruptcy. Claimants argued that the strategy is a misuse of the US bankruptcy code — and on Monday, a panel of judges agreed.

Over the past several years, Massachusetts-based contractor Charles River Laboratories has been busy on the M&A front, with the latest, $50 million buyout coming Monday for a provider of high-throughput screening solutions for discovery research.

Chicago-based SAMDI Tech will now be folded into Charles River’s discovery and safety assessment division, Charles River announced.

The $50 million in cash is for the 80% of SAMDI that Charles River didn’t previously own. Other financial details on the deal were not disclosed.